Categories
- About MIMS Ireland
- New Products
- New Presentations
- New this Month
- Discontinued Products
- New Clinical Evidence
- Clinical Specials
- Irish Medicines Board
- Medicines and Sport
Archives
- December 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
- January 2008
- November 2007
- October 2007
Tagcloud
ACE inhibitor, acetylcholinesterase inhibitor, aciclovir, acne, acute coronary syndrome, acute lymphoblastic leukaemia, ADHD, advanced prostate cancer, advanced renal cell carcinoma, advanced soft tissue sarcoma, adverse reaction, agomelatine, agoraphobia, alendronic acid, alfuzosin, algorithm, aliskiren, allergic rhinitis, allopurinol, alpha1-proteinase inhibitor, Alzheimer's, amantadine hydrochloride, ambrisentan, aminosalicylate, amlodipine, amoxicillin, anaemia, angina pectoris, anidulafungin, ankylosing spondylitis, anti-doping, anti-heparin, anti-human thymocyte immunoglobulin, antibacterial, antibiotic, anticoagulant, antidepressant, antineoplastic, antipsychotic, antiretroviral, antiretroviral therapy, anxiety, aromatase inhibitor, asthma, atazanavir, azacitidine, bacterial infections, BCG Vaccine, beclometasone, behaviour disorders, betamethasone, bevacizumab, bicalutamide, bipolar disorder, bisoprolol fumarate, bisphosphonates, black patients, bladder cancer, bowel cleansing, BPH, breakthrough pain, breast cancer, brinzolamide, bronchospasm, budesonide, bulimia nervosa, calcipotriol, calcium, candesartan, Candida albicans, candidiasis, carbetocin, carbidopa, cardiac insufficiency, cardiovascular disease, cefaclor, ceftriaxone, cefuroxime, cephalosporin, cetirizine, CHF, cholecalciferol, chronic constipation, chronic heart failure, Chronic Kidney Disease, chronic myeloid leukaemia, chronic myelomonocytic leukaemia, chronic pain, chronic pulmonary infection, ciprofloxacin, citalopram hydrobromide, clarithromycin, clavulanic acid, clopidogrel, clotrimazole, clozapine, colorectal cancer, contraception, COPD, coronary artery disease, Crohn’s Disease, cystic fibrosis, dabigatran etexilate, daptomycin, darunavir, dasatinib, degarelix, dementia, depression, dermatophytes, dermatophytose, desogestrel, diabetes, diclofenac, dienogest, diphteria, discontinuations, domperidone, donepezil, doxazosin, doxycycline, drospirenone, duodenal ulcer, dyslipidaemia, eczema, eletriptan, emetogenic cancer chemotherapy, enalapril, endocarditis, entacapone, epigastric bloating, epilepsy, epirubicin, epoetin, ErbB2 (HR2) receptors, erythropoiesis-stimulating agents, esomeprazole, estradiol, ethinylestradiol, etravirine, everolimus, exemestane, faecal impaction, famciclovir, fentanyl, fesoterodine, fever, filgrastim, finasteride, fluconazole, fluoxetine, flurbiprofen, fluvastatin, folate, folic acid, follicular development stimulation, follicular lymphoma, follitropin alpha, fosprepitant, fungal infections, gabapentin, gastric cancer, gastric ulcer, gastroduodenal ulcer, gemcitabine, gestodene, gliclazide, glucosamine sulphate, gonorrhoea, GORD, growth failure, H1N1, hayfever, heart failure, heart rate, Helicobacter pylori, hepatic failure, hepatitis, hepatocellular carcinoma, herpes, hip or knee replacement surgery, hip osteoarthritis, HIV, hyaluronic acid, hydrochlorothiazide, Hylan G-F 20, hypercholesterolaemia, hyperlipidaemia, hyperphosphataemia, hypertension, hyperuricaemia, hypoactive sexual desire disorder, ibritumomab, ibuprofen, IGF-1 deficiency, IMB, immunosuppression, indacaterol, indapamide, infections, inflammation, influenza, insomnia, interferon beta-1a, iobetasol, IOP, ipatropium bromide, irinotecan, Irish Sports Council, ischaemic stroke, isotretinoin, ivabradine, Kaposi's sarcoma, kidney cancer, kidney disease, knee osteoarthritis, lacosamide, lamotrigine, lansoprazole, lapatinib, laropiprant, lenalidomide, lercanidipine, leuprorelin acetate, levodopa, levonorgestrel, liraglutide, lisinopril, losartan, lutropin alpha, Lyme disease, macrogol, magnesium, mania, maraviroc, mecasermin, melatonergic, melatonin, meloxicam, memantine, mesalazine, metastatic colorectal carcinoma, metformin, methadone, methylnaltrexone bromide, methylphenidate hydrochloride, mexiletine hydrochloride, micafungin, migraine, mirtazapine, mixed dyslipidaemia, moxifloxacin, multiple myeloma, multiple sclerosis, muscular disorders, myelodysplastic syndromes, myocardial infarction, naloxone, naratriptan, nasal congestion, nausea, nebivolol, nephropathy, neural tube defects, neutropenia, NICE guidelines, nicotine, nicotinic acid, nilotinib, NSCLC, nutrition, OCD, ocular hypertension, olanzapine, olmesartan, omeprazole, ondensetron, open angle glaucoma, opioid addiction, opioid analgesic, opioid-induced constipation, oseltamivir, osteoarthritis, osteonecrosis of the jaw, osteoporosis, otitis, ovarian cancer, overactive bladder syndrome, oxycodone, paclitaxel, pain, pancreatic cancer, pancreatic exocrine insufficiency, pancreatin, panic disorder, panitumumab, pantoprazole, paracetamol, Parkinson’s, partial-onset seizures, patch, pemetrexed, peptic ulcer, perindopril, peripheral arterial disease, peripheral neuropathic pain, pertussis, piperacillin, Pityriasis versicolor, poliomyelitis, post transplantation hyperlipidaemia, post-operative pain, post-traumatic stress disorder, PPIs, pramipexole, pravastatin, pregnancy, pricing policy, primary hypercholesterolaemia, probiotics, prostate cancer, protamine sulphate, Pseudomonas aeruginosa, psoriasis, psychotic disorders, pulmonary arterial hypertension, pulmonary embolism, quetiapine, raltegravir, ramipril, ranolazine, rasagiline, recombinant IGF-1, reflux oesophagitis, renal disease, renin inhibitor, Restless Legs Syndrome, rheumatoid arthritis, ribavirin, ringworm, risedronate sodium, risperidone, rivaroxaban, rivastigmine, romiplostim, ropinirole, rosacea, RTI, S. aureus, salbutamol, sarcoma, saxagliptin, schizophrenia, SCLC, sertraline, sevelamer carbonate, severe pain, simvastatin, sitagliptin, smoking cessation, sodium alginate, solide organ transplantation, sorafenib, sore throat, spasticity, spinal cord injury, sport, sprain, statins, stroke, strontium ranelate, suicide, systemic embolisation, telmisartan, temsirolimus, terbinafine, testosterone, tetanus, thalidomide, thrombocytopenic purpura, thrush, tibolone, timolol, tinea, tiotropium, tipranavir, tizanidine, tobramycin, tocilizumab, topotecan, trabectedin, tramadol, Trichophyton, trimethoprim, trospium chloride, ustekinumab, UTI, vaccine, valaciclovir, valproate, valsartan, varenicline, venlafaxine, venous thromboembolism, venous thrombosis, vildagliptin, vinorelbine, vitamin D, vomiting, WADA, warfarin, wound, zanamivir, zoledronic acid, Zollinger-Ellison syndrome
«Previous article | Next article»
Blopress Plus

Company: Takeda UK Ltd.
Legal category: Prescription. GMS. Sport prohibited.
Active ingredients: Candesartan cilexetil/hydrochlorothiazide 8mg/12.5mg, 16mg/12.5mg, 32mg/12.5mg, 32mg/25mg.
Description: 8mg/12.5mg: White, oval tablets with a score with 8 C on both sides. 16mg/12.5mg: Light pink, oval tablets with a score with 16│C on both sides. 32mg/12.5mg: Light yellow, oval tablets with 32│C1 on both sides. 32mg/25mg: Light pink, oval tablets with 32│C2 on both sides.
Presentation: 8mg/12.5mg-28, €15.81; 16mg/12.5mg-28, €19.22; 32mg/12.5mg-28, €24.63; 32mg/25mg-28, €24.63.
Indication: Essential Hypertension, where monotherapy with candesartan cilexetil or hydrocholorothiazide (HCTZ) is not sufficient.
Pharmacology: Candesartan is an angiotensin II receptor antagonist, selective for AT1 receptors, with tight binding to and slow dissociation from the receptor. It has no agonist activity. Hydrochlorothiazide inhibits the active reabsorption of sodium, mainly in the distal kidney tubules, and promotes the excretion of sodium, chloride and water. The renal excretion of potassium and magnesium increases dose-dependently, while calcium is reabsorbed to a greater extent. Hydrochlorothiazide decreases plasma volume and extracellular fluid and reduces cardiac output and blood pressure. During long-term therapy, reduced peripheral resistance contributes to the blood pressure reduction.
Dosage: Adult: 1 tablet once daily. Titrate candesartan cilexetil dose before switching to Blopress Plus (esp. in renal impairment and volume depleted patients). When clinically appropriate a direct change from monotherapy to Blopress Plus may be considered. Mild-moderate renal impairment: Initially 4mg candesartan. Mild to moderate hepatic impairment: Initially, 2mg candesartan. Elderly: As per adults. Children: Safety and efficacy not established.
Contraindications: Hypersensitivity to any component of Blopress Plus. Pregnancy, lactation. Severe hepatic impairment and/or cholestasis. Severe renal impairment. Refractory hypokalaemia and hypercalcaemia. Gout.
Special precautions: Not recommended: Primary aldosteronism. Renal impairment: Monitor potassium, creatinine and uric acid levels. No experience in patients with a recent kidney transplant. Caution: Renal artery stenosis (risk of increased blood urea and serum creatinine), impaired hepatic function or progressive liver disease, aortic or mitral valve stenosis, obstructive hypertrophic cardiomyopathy. Correct intravascular volume and/or sodium depletion before starting treatment. Hypotension may occur during anaesthesia and surgery. Monitor serum electrolytes. Discontinue before carrying out tests for parathyroid function. May impair glucose tolerance. Hypersensitivity reactions to HCTZ may occur (particularly if history of allergy or bronchial asthma). Exacerbation or activation of SLE reported with thiazides. Contains lactose.
Drug interactions: Caution: Skeletal muscle relaxants, drugs associated with potassium loss and hypokalaemia (e.g. other kaliuretic diuretics, laxatives, amphotericin, carbenoxolone, penicillin G sodium, salicylic acid derivates), calcium supplements, Vitamin D, beta-blockers, diazoxide, anticholinergic agents (e.g. atropine, beperiden), amantadine, cytotoxic drugs (e.g. cyclophosphamide, methotrexate), steroids or adrenocorticotropic hormone (ACTH), antidiabetic drugs (incl. insulin), pressor amines (e.g. adrenaline), iodinated contrast media, lithium, K+ -sparing diuretics, K+ supplements, salt substitutes containing K+, or other medicinal products that may increase K+ levels. Possible interaction with NSAIDs. Antihypertensive effect may be enhanced by other antihypertensives. Absorption of HCTZ is reduced by colestipol or cholestyramine.
Adverse drug reactions: Dizziness/vertigo, hyperglycaemia, hyperuricaemia, electrolyte imbalance (incl. hyponatraemia and hypokalaemia), glycosuria, weakness, increases in cholesterol and triglycerides.
Full prescribing information and references available from Takeda UK Ltd. Telephone: +44 (1628) 537900. Fax: +44 (1628) 526615.
Posted in 02 New products on 01 November 2009
Tags: candesartan, hydrochlorothiazide, hypertension
More articles from IMT MIMS Ireland
